Memorandum on Addressing Misleading Direct-To-Consumer Prescription Drug Advertisements

Memorandum on Addressing Misleading Direct-To-Consumer Prescription Drug AdvertisementsPresident Donald J. Trump issued a memorandum directing federal agencies to tighten oversight of prescription drug advertising, citing concerns that direct-to-consumer ads often mislead the public, understate risks, and promote expensive brand-name drugs over cheaper generics.Key Directives:The Secretary of Health and Human Services must ensure greater transparency and accuracy in advertising, requiring clearer disclosure of drug risks.The FDA Commissioner is tasked with stricter enforcement of the Federal Food, Drug, and Cosmetic Act, ensuring ads are truthful and non-misleading.The initiative emphasizes protecting the physician-patient relationship, reducing bias toward costly drugs, and restoring public trust in medical information.The memorandum reflects the administration’s focus on giving Americans fair, balanced, and complete information about prescription drugs to safeguard public health.